Official Journal of the Human Genome Organisation
Tumour | Mutation | Study | Number of matched samples | Technique used | Medium | Mutation rate in plasma/serum | Mutation rate in tumour | Concordance between plasma/serum and tumour (%) |
---|---|---|---|---|---|---|---|---|
Non-small cell lung cancer | EGFR (Exon 19 deletions and p.L858R) | Kimura et al. (2007) | 42 | Scorpion-ARMS | Serum | 19% | 21.4% | 92.9 |
Maheswaran et al. (2008) | 12a | Scorpion-ARMS | Plasma | N/A | N/A | 33 | ||
Rosell et al. (2009) | 164a | PNA mediated PCR | Serum | N/A | N/A | 59 | ||
KRAS | Wang et al. (2010) | 273 | PCR–RFLP | Plasma | 12.8% | 11% | 76.7 | |
Pancreatic cancer | KRAS | Castells et al. (1999) | 39 | PCR–RFLP | Plasma | 23% | 72% | 32 |
Breast cancer | PIK3CA | Board et al. (2010) | 41 | Scorpion-ARMS | Plasma | 19.5% | 24% | 95 |
Angenendt et al. (2010) | 50 | BEAMing | Plasma | 30% | 30% | 100 | ||
Cutaneous melanoma | BRAF | Board et al. (2009) | 96 | ARMS | Serum | 26.6% | 47% | 76 |
Pinzani et al. (2010) | 56 | Allele specific real time PCR | Plasma | 42% | 51% | 80 |